Enodia Therapeutics has successfully closed a €20.7 million seed financing round, marking the third major seed success for Argobio Studio —a venture-building platform in which Angelini Ventures is a strategic investor.

Co-led by Elaia, Pfizer Ventures, and Bpifrance, this round validates Argobio's operational venture-building model designed to rapidly translate Europe's leading scientific innovation into globally competitive biotech companies.

Enodia, co-founded by Argobio and rooted in Institut Pasteur's pioneering research, is developing novel small-molecule therapies that leverage machine learning and proteomics to enable targeted protein degradation at the point of synthesis, addressing high-unmet-need conditions in inflammatory, autoimmune, oncology, and viral infections.

Download the Full Press Release